Evaluations of Biomarker Status Changes between Primary and Recurrent Tumor Tissue Samples in Breast Cancer Patients

Table 3

Conversion rates of receptor status between primary tumor and metastasis.

Markers	Total	HR-positive (%)	HER2 amplified (%)	Triple-negative (%)
ER
No conversion	49	23 (76.7%)	18 (75.0%)	8 (61.5%)
From (+) to (−)	8	6 (20.0%)	2 (8.3%)	0
From (−) to (+)	10	1 (3.3%)	4 (16.7%)	5 (38.5%)
Total	67	30 (100%)	24 (100%)	13 (100%)
PR
No conversion	41	12 (40.0%)	20 (83.3%)	9 (69.2%)
From (+) to (−)	17	14 (46.7%)	3 (12.5%)	0
From (−) to (+)	9	4 (13.3%)	1 (4.2%)	4 (30.8%)
Total	67	30 (100%)	24 (100%)	13 (100%)
HER2
No conversion	52	24 (80.0%)	19 (79.2%)	9 (69.2%)
From (+) to (−)	5	0	5 (20.8%)	0
From (−) to (+)	10	6 (20.0%)	0	4 (30.8%)
Total	67	30 (100%)	24 (100%)	13 (100%)